Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
暂无分享,去创建一个
Marc P. Bonaca | E. Braunwald | D. Morrow | C. McCabe | B. Scirica | K. Fox | E. Veltri | J. Strony | Gail Berman | P. Fish | C. Mccabe